Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control
A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Research Site
-
Chongqing, China
- Research Site
-
Tianjin, China
- Research Site
-
-
Anhui
-
Hefei, Anhui, China
- Research Site
-
-
Fujian
-
Fuzhou, Fujian, China
- Research Site
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Research Site
-
-
Hebei
-
Shijiazhuang, Hebei, China
- Research Site
-
-
Hunan
-
Changsha, Hunan, China
- Research Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Research Site
-
-
Jilin
-
Changchun, Jilin, China
- Research Site
-
-
Liaoning
-
Dalian, Liaoning, China
- Research Site
-
Shenyang, Liaoning, China
- Research Site
-
-
Shanghai
-
Shanghai, Shanghai, China
- Research Site
-
-
Sichuan
-
Chengdu, Sichuan, China
- Research Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Research Site
-
-
-
-
-
Coimbatore, India
- Research Site
-
-
Andhra Pradesh
-
Hyderabaad, Andhra Pradesh, India
- Research Site
-
-
Karnataka
-
Bangalore, Karnataka, India
- Research Site
-
Mangalore, Karnataka, India
- Research Site
-
-
Maharashtra
-
Mumbai, Maharashtra, India
- Research Site
-
Nagpur, Maharashtra, India
- Research Site
-
Pune, Maharashtra, India
- Research Site
-
-
-
-
-
Daegu, Korea, Republic of
- Research Site
-
Seoul, Korea, Republic of
- Research Site
-
-
Chonbuk
-
Jeonju, Chonbuk, Korea, Republic of
- Research Site
-
-
-
-
-
Cebu City, Philippines
- Research Site
-
Makati City, Philippines
- Research Site
-
Manila, Philippines
- Research Site
-
Marikina City, Philippines
- Research Site
-
Quezon City, Philippines
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with Type 2 diabetes
- Patients should be drug naïve ie, not received medical treatment for diabetes,
- HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)
Exclusion Criteria:
- Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes),
- Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
oral tablet, once daily for 24 weeks
|
|
Experimental: Saxagliptin 5mg
|
5mg, oral tablet, once daily for 24 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)
Time Frame: Baseline , Week 24
|
Adjusted* mean change from baseline in HbA1c achieved with saxagliptin 5 mg versus placebo at week 24 (LOCF, Full Analysis set).
HbA1c is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value.
HbA1c data were excluded on and after rescue medication.
|
Baseline , Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute Change (mmol/L) From Baseline to Week 24 in Fasting Plasma Glucose (FPG)
Time Frame: Baseline, Week 24
|
Adjusted* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at week 24 (Last Observation Carried Forward (LOCF), Full Analysis set).
FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value.
FPG data were excluded on and after rescue medication.
|
Baseline, Week 24
|
|
Absolute Change (mg/dL) From Baseline to Week 24 in Fasting Plasma Glucose (FPG)
Time Frame: Baseline, Week 24
|
Adjusted* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at week 24 (LOCF, Full Analysis set).
FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value.
FPG data were excluded on and after rescue medication.
|
Baseline, Week 24
|
|
Absolute Change (mmol*Min/L) From Baseline to Week 24 in Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During Mixed Meal (Instant Noodles) Tolerance Tests (MMTT) in All MMTT Participants
Time Frame: Baseline , Week 24
|
Adjusted* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg versus placebo at week 24 (LOCF, Full Analysis set).
Trapezoidal method was used to compute AUC under the 3 hour PPG curve.
Change from baseline for each subject is computed as the week 24 value minus the baseline value.PPG data were excluded on and after rescue medication
|
Baseline , Week 24
|
|
Absolute Change (mg*Min/dL) From Baseline to Week 24 in Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During Mixed Meal (Instant Noodles) Tolerance Tests (MMTT) in All MMTT Participants
Time Frame: Baseline , Week 24
|
Adjusted* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg versus placebo at week 24 (LOCF, Full Analysis set).
Trapezoidal method was used to compute AUC under the 3 hour PPG curve.
Change from baseline for each subject is computed as the week 24 value minus the baseline value.PPG data were excluded on and after rescue medication
|
Baseline , Week 24
|
|
Proportion of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c <7.0% at Week 24
Time Frame: Baseline, Week 24
|
Proportion of participants (expressed in percentage of total participants) achieving HbA1c < 7.0% for saxagliptin versus placebo at week 24.
HbA1c Data were excluded on and after rescue medication
|
Baseline, Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Peter Öhman, MD, PhD, AstraZeneca, Wilmington, USA
- Study Chair: Deborah Price, MSc, AstraZeneca, Wilmington, USA
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Saxagliptin
Other Study ID Numbers
Other Study ID Numbers
- D1680C00005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.